Katharina Sinn

Vienna, 1090, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 34 publications

MiR-21 Is a Novel Diagnostic and Prognostic Circulating Biomarker in Pleural Mesothelioma.

MiR-21 Is a Novel Diagnostic and Prognostic Circulating Biomarker in Pleural Mesothelioma.

Journal: Diagnostics (Basel, Switzerland)

Published: March 03, 2026

Current advances in extended resections for non-small cell lung cancer-a narrative review.

Current advances in extended resections for non-small cell lung cancer-a narrative review.

Journal: Translational lung cancer research

Published: March 01, 2026

Reactive Oxygen Species Drive Cell Migration and PD-L1 Expression via YB-1 Phosphorylation in Pleural Mesothelioma.

Reactive Oxygen Species Drive Cell Migration and PD-L1 Expression via YB-1 Phosphorylation in Pleural Mesothelioma.

Journal: Antioxidants (Basel, Switzerland)

Published: November 07, 2025

Surgical Results after Neoadjuvant Nivolumab and Platinum-based Chemotherapy for Resectable Lung Cancer. A Multicentre European Real Clinical Practice Analysis.

Surgical Results after Neoadjuvant Nivolumab and Platinum-based Chemotherapy for Resectable Lung Cancer. A Multicentre European Real Clinical Practice Analysis.

Journal: European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery

Published: July 30, 2025

The Mesothelioma Systemic Inflammation Score Is Independently Associated with Overall Survival and Predicts Benefit of Multimodality Treatment in Pleural Mesothelioma.

The Mesothelioma Systemic Inflammation Score Is Independently Associated with Overall Survival and Predicts Benefit of Multimodality Treatment in Pleural Mesothelioma.

Journal: Cancers

Published: March 31, 2025

Impact of Neoadjuvant and Adjuvant Pleural Intensity-Modulated Radiotherapy in Multimodality Treatment for Malignant Pleural Mesothelioma.

Impact of Neoadjuvant and Adjuvant Pleural Intensity-Modulated Radiotherapy in Multimodality Treatment for Malignant Pleural Mesothelioma.

Journal: Thoracic cancer

Published: November 17, 2024

High circulating activin A plasma levels are associated with tumour stage and poor survival in treatment-naive lung squamous cell cancer patients.

High circulating activin A plasma levels are associated with tumour stage and poor survival in treatment-naive lung squamous cell cancer patients.

Journal: Translational oncology

Published: July 01, 2024

Circulating FGF18 is decreased in pleural mesothelioma but not correlated with disease prognosis.

Circulating FGF18 is decreased in pleural mesothelioma but not correlated with disease prognosis.

Journal: Thoracic cancer

Published: April 07, 2023

Neoadjuvant immune-checkpoint inhibitors in lung cancer - a primer for radiologists.

Neoadjuvant immune-checkpoint inhibitors in lung cancer - a primer for radiologists.

Journal: European journal of radiology

Published: February 01, 2023

Trabectedin Is Active against Two Novel, Patient-Derived Solitary Fibrous Pleural Tumor Cell Lines and Synergizes with Ponatinib.

Trabectedin Is Active against Two Novel, Patient-Derived Solitary Fibrous Pleural Tumor Cell Lines and Synergizes with Ponatinib.

Journal: Cancers

Published: September 10, 2022

Mesothelioma-associated fibroblasts enhance proliferation and migration of pleural mesothelioma cells via c-Met/PI3K and WNT signaling but do not protect against cisplatin.

Mesothelioma-associated fibroblasts enhance proliferation and migration of pleural mesothelioma cells via c-Met/PI3K and WNT signaling but do not protect against cisplatin.

Journal: Journal of experimental & clinical cancer research : CR

Published: September 08, 2022

Corrigendum to 'Neoadjuvant chemoradiotherapy is superior to chemotherapy alone in surgically treated stage III/N2 non-small-cell lung cancer: a retrospective single-center cohort study': [ESMO Open Volume 7, Issue 2, April 2022, 100466].

Corrigendum to 'Neoadjuvant chemoradiotherapy is superior to chemotherapy alone in surgically treated stage III/N2 non-small-cell lung cancer: a retrospective single-center cohort study': [ESMO Open Volume 7, Issue 2, April 2022, 100466].

Journal: ESMO open

Published: June 13, 2022

Showing 1-12 of 34

Last Updated: 09/26/2026